CEO & Founder
Dr. Hao Pang is a founder and CEO of Quantum Science Ltd. Hao led the initial fundraising, developed the global business strategy, built the team and led the technology and IP development. Prior to found Quantum Science, Hao held a vice president role at a leading LSE listed technology company, where he led a multi-million USD technology licensing deal, developed the supply chain and successfully introduced the technology into the global electronic markets. Dr. Hao Pang has 18 years materials research and commercialisation experience. He has a PhD in Materials Chemistry from the University of Strathclyde and an MBA from Manchester Business School.
Mr. Steve Kelly is a highly experienced non-executive director and business advisor with over 25 years at executive level. He is CEO and founder of Northstar Advisors, a strategy advisory for technology start-ups, and the former CEO and founder of SmartKem Limited, a leading company in the field of organic semiconductors for flexible electronics between 2008 to 2018. Previously, he was co-founder and CEO of Datalase Ltd between 2001 to 2008, where he successfully restructured and rebranded the company before its acquisition by SATO Holdings, and CTO of Kromacrop Inc. between 1993 to 2001. Steve gained his Bachelor’s in Science from Manchester Metropolitan University in Polymer Science and Technology.
Chief Scientific Advisor
Professor Peter Skabara holds the Ramsay Chair of Chemistry at the University of Glasgow and has published over 190 papers and patents. He is a world leader in the synthesis of novel macromolecules and polymers as organic semiconductors, in particular, well-defined, multifunctional molecular systems, work recognised by a Royal Society Wolfson Merit Award. He is the recipient of the Royal Society of Chemistry’s Peter Day Award. His research management experience includes 16 EPSRC grants and 4 EU grants and was the Editor-in-Chief of the Journal of Materials Chemistry C since its inception in 2013 until 2019. He has served as theme lead and co-chair for a number of international conferences. In his position in Glasgow he is the Director of Research.
Dr Karl Bamford is a highly experienced professional in medical technologies and go to market strategies, whose international career has been based on identifying, developing and delivering creative, entrepreneurially driven solutions, and leading dynamic, highly focused innovation teams. He is currently CEO of Vodus Medical which develops antimicrobial polymers for healthcare applications and Director of Genesis Pathway AI developing artificial intelligence for drug discovery and runs his consultancy company supporting SME’s. Prior to this Karl was a Manager of Innovation at Central Manchester University Hospital NHS Trust, a Manager at OpTIC Centre (formally know as OpTIC Technium) and Sales Manager at AG Electro Optics. Karl gained his PhD in Photonics from Cranfield University and BEng in Electronic Engineering from Birmingham City University.
Dr Helen Hu has a wealth of experience in finance and M&A, international fundraising and operations management. She is currently a consulting partner at RSM China and previously held several senior positions including CFO at Mirach Energy (listed on SGX), General Manager of Beijing Xirunsi and Founder of China Business ABC Limited. Helen held MSc. and PhD in Economics and Finance of the University of York, UK
Professor Tony Heagerty is an international authority in high blood pressure and cardiovascular diseases. He is the Head of School at the Medical Sciences at the University of Manchester and former President of British Hypertension Society. Tony was a Founding Member of the Academy of Medical Sciences and served on the Nominations Committee of the Royal College of Physicians. He is a member of the Institute of Health Sciences Diabetes and Obesity Research Network, and a Fellow of the High Blood Pressure Council of the American Heart Association. Tony obtained his medical degree from the Middlesex Hospital Medical School and his MD in Leicester.